References
- Simionescu DT. Prevention of calcification in bioprosthetic heart valves: challenges and perspectives. Expert Opin Biol Ther 2004;4:1971-85. https://doi.org/10.1517/14712598.4.12.1971
- Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci U S A 1993;90:11391-5. https://doi.org/10.1073/pnas.90.23.11391
- Cooper DK, Koren E, Oriol R. Oligosaccharides and discordant xenotransplantation. Immunol Rev 1994;141:31-58. https://doi.org/10.1111/j.1600-065X.1994.tb00871.x
- Sandrin MS, McKenzie IF. Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 1994;141:169-90. https://doi.org/10.1111/j.1600-065X.1994.tb00877.x
- Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993;14:480-2. https://doi.org/10.1016/0167-5699(93)90261-I
- Konakci KZ, Bohle B, Blumer R, et al. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest 2005;35:17-23. https://doi.org/10.1111/j.1365-2362.2005.01441.x
- Villa ML, De Biasi S, Pilotto F. Residual heteroantigenicity of glutaraldehyde-treated porcine cardiac valves. Tissue Antigens 1980;16:62-9.
- Schoen FJ. Editorial: Are immune mechanisms important in tissue heart valve failure? A debate. J Heart Valve Dis 2001;10:458-9.
- Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation 1997;95:479-88. https://doi.org/10.1161/01.CIR.95.2.479
- Park CS, Park SS, Choi SY, Yoon SH, Kim WH, Kim YJ. Anti alpha-gal immune response following porcine bioprosthesis implantation in children. J Heart Valve Dis 2010;19:124-30.
- Ueda Y, Torrianni MW, Coppin CM, Iwai S, Sawa Y, Matsuda H. Antigen clearing from porcine heart valves with preservation of structural integrity. Int J Artif Organs 2006; 29:781-9.
- Griffiths LG, Choe LH, Reardon KF, Dow SW, Christopher Orton E. Immunoproteomic identification of bovine pericardium xenoantigens. Biomaterials 2008;29:3514-20. https://doi.org/10.1016/j.biomaterials.2008.05.006
- Park S, Kim WH, Choi SY, Kim YJ. Removal of alpha-Gal epitopes from porcine aortic valve and pericardium using recombinant human alpha galactosidase A. J Korean Med Sci 2009;24:1126-31. https://doi.org/10.3346/jkms.2009.24.6.1126
- Kim YG, Gil GC, Harvey DJ, Kim BG. Structural analysis of alpha-Gal and new non-Gal carbohydrate epitopes from specific pathogen-free miniature pig kidney. Proteomics 2008;8:2596-610. https://doi.org/10.1002/pmic.200700972
- Yi KS, Lee S, Kang YH, et al. Weak response of porcine C5a receptor towards human C5a in miniature pig endothelial cells and PMNs. Xenotransplantation 2007;14:563-71. https://doi.org/10.1111/j.1399-3089.2007.00421.x
- Stacchino C, Bona G, Bonetti F, Rinaldi S, Della Ciana L, Grignani A. Detoxification process for glutaraldehyde-treated bovine pericardium: biological, chemical and mechanical characterization. J Heart Valve Dis 1998;7:190-4.
- Koma M, Miyagawa S, Honke K, et al. Reduction of the major xenoantigen on glycosphingolipids of swine endothelial cells by various glycosyltransferases. Glycobiology 2000;10:745-51. https://doi.org/10.1093/glycob/10.7.745
- Chen RH, Mitchell RN, Kadner A, Adams DH. Differential galactose alpha(1,3) galactose expression by porcine cardiac vascular endothelium. Xenotransplantation 1999;6:169-72. https://doi.org/10.1034/j.1399-3089.1999.00024.x
- Kin T, Nakajima Y, Aomatsu Y, et al. Humoral human xenoreactivity against isolated pig pancreatic islets. Surg Today 2000;30:821-6. https://doi.org/10.1007/s005950070065
- Manji RA, Zhu LF, Nijjar NK, et al. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation 2006;114:318-27. https://doi.org/10.1161/CIRCULATIONAHA.105.549311
- Kasimir MT, Rieder E, Seebacher G, Wolner E, Weigel G, Simon P. Presence and elimination of the xenoantigen gal (alpha1, 3) gal in tissue-engineered heart valves. Tissue Eng 2005;11:1274-80. https://doi.org/10.1089/ten.2005.11.1274
- Carpentier A, Lemaigre G, Robert L, Carpentier S, Dubost C. Biological factors affecting long-term results of valvular heterografts. J Thorac Cardiovasc Surg 1969;58:467-83.
- Kozlowski T, Monroy R, Xu Y, et al. Anti-Gal(alpha)1-3Gal antibody response to porcine bone marrow in unmodified baboons and baboons conditioned for tolerance induction. Transplantation 1998;66:176-82. https://doi.org/10.1097/00007890-199807270-00006
- Cooper DK, Thall AD. Xenoantigens and xenoantibodies: their modification. World J Surg 1997;21:901-6. https://doi.org/10.1007/s002689900324
- Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988;263:17755-62.
- Farivar RS, Filsoufi F, Adams DH. Mechanisms of Gal(alpha) 1-3Gal(beta)1-4GlcNAc-R (alphaGal) expression on porcine valve endothelial cells. J Thorac Cardiovasc Surg 2003;125:306-14. https://doi.org/10.1067/mtc.2003.76
Cited by
- In VivoEfficacy of Alpha-Galactosidase as Possible Promise for Prolonged Durability of Bioprosthetic Heart Valve Using Alpha1,3-Galactosyltransferase Knockout Mouse vol.19, pp.21, 2012, https://doi.org/10.1089/ten.tea.2013.0062
- Tissue engineering of autologous heart valves: a focused update vol.10, pp.1, 2012, https://doi.org/10.2217/fca.13.96
- In vivo efficacy for novel combined anticalcification treatment of glutaraldehyde-fixed cardiac xenograft using humanized mice vol.29, pp.7, 2012, https://doi.org/10.1177/0885328214552710
- Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review) vol.37, pp.1, 2016, https://doi.org/10.3892/ijmm.2015.2397
- Microstructure and Mechanical Property of Glutaraldehyde-Treated Porcine Pulmonary Ligament vol.138, pp.6, 2012, https://doi.org/10.1115/1.4033300
- Physical equivalency of wild type and galactose α 1,3 galactose free porcine pericardium; a new source material for bioprosthetic heart valves vol.41, pp.None, 2012, https://doi.org/10.1016/j.actbio.2016.06.007
- In vitro comparative assessment of decellularized bovine pericardial patches and commercial bioprosthetic heart valves vol.12, pp.1, 2017, https://doi.org/10.1088/1748-605x/aa5644
- Xenoantigenicity of porcine decellularized valves vol.12, pp.None, 2012, https://doi.org/10.1186/s13019-017-0621-5
- In Vitro Detection System to Evaluate the Immunogenic Potential of Xenografts vol.24, pp.5, 2018, https://doi.org/10.1089/ten.tec.2017.0532
- Structure and Rheological Properties of Bovine Aortic Heart Valve and Pericardium Tissue: Implications in Bioprosthetic and Tissue-Engineered Heart Valves vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/3290370
- Alteration of the extracellular matrix and alpha‐gal antigens in the rat lung scaffold reseeded using human vascular and adipogenic stromal cells vol.13, pp.11, 2019, https://doi.org/10.1002/term.2923
- Bovine pericardial extracellular matrix niche modulates human aortic endothelial cell phenotype and function vol.9, pp.1, 2012, https://doi.org/10.1038/s41598-019-53230-1
- Biomaterials in Valvular Heart Diseases vol.8, pp.None, 2012, https://doi.org/10.3389/fbioe.2020.529244
- Mammalian Pericardium‐Based Bioprosthetic Materials in Xenotransplantation and Tissue Engineering vol.15, pp.8, 2012, https://doi.org/10.1002/biot.201900334
- Toward acellular xenogeneic heart valve prostheses: Histological and biomechanical characterization of decellularized and enzymatically deglycosylated porcine pulmonary heart valve matrices vol.27, pp.5, 2012, https://doi.org/10.1111/xen.12617
- Xenotransplantation literature update for September – October 2020 vol.28, pp.1, 2012, https://doi.org/10.1111/xen.12665
- In Situ “Humanization” of Porcine Bioprostheses: Demonstration of Tendon Bioprostheses Conversion into Human ACL and Possible Implications for Heart Valve Bioprostheses vol.8, pp.1, 2012, https://doi.org/10.3390/bioengineering8010010
- The useful agent to have an ideal biological scaffold vol.22, pp.2, 2021, https://doi.org/10.1007/s10561-020-09881-w
- Decellularized xenografts in regenerative medicine: From processing to clinical application vol.28, pp.4, 2012, https://doi.org/10.1111/xen.12683